A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PST / primary systemic therapy

[Related PubMed/MEDLINE]
Total Number of Papers: 76
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PST  (>> Co-occurring Abbreviation)
Long Form:   primary systemic therapy
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
1  2020 Changes and prognostic values of tumor-infiltrating lymphocyte subsets after primary systemic therapy in breast cancer. RCB, TIL
2  2020 Clinical Utility of 18F-FDG PET/CT in Staging Localized Breast Cancer Before Initiating Preoperative Systemic Therapy. CTBS
3  2020 Radiotherapy after primary CHEMotherapy (RAPCHEM): Practice variation in a Dutch registration study (BOOG 2010-03). BC, RAPCHEM, RT, SG
4  2019 Evaluation of MRI accuracy after primary systemic therapy in breast cancer patients considering tumor biology: optimizing the surgical planning. BCS, MRI, pCR, TN
5  2019 Expression profile of CADM1 and CADM4 in triple negative breast cancer with primary systemic therapy. CADM, TNBC
6  2019 Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: Time trend, imaging staging power and nodal downstaging according to molecular subtype. SNB
7  2019 When Can We Avoid Postmastectomy Radiation Following Primary Systemic Therapy? BCSS, DM, LRR, LVI, OS, PMRT
8  2018 Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer. ER, HER2, PR
9  2018 Primary medical therapy and breast conservation treatment: the medical oncology perspective. AST, pCR
10  2018 Shear Wave Speed of the Lesion in Preoperative Breast Ultrasonography: Association with Disease-free Survival of Patients with Primary Operable Invasive Breast Cancer. CI, HR, SWS, US
11  2018 Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients with breast cancer converting from cN+ to ycN0 through primary systemic therapy (PST). CI, ER, OR
12  2018 Validation of a Nomogram Predicting Non-Sentinel Lymph Node Metastases among Patients with Breast Cancer after Primary Systemic Therapy - a transSENTINA Substudy. AUC, OR, SLN
13  2017 Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution. CT, ET, OS, OSCT
14  2017 Predictive and prognostic value of FDG-PET/CT imaging and different response evaluation criteria after primary systemic therapy of breast cancer. pCR
15  2016 Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. HER2, OS, pCR, RFS
16  2016 The position and current status of radiation therapy after primary systemic therapy in breast cancer: a national survey-based expert consensus statement. BCS, RT, SNB
17  2015 Complexity of Response Evaluation During Primary Systemic Therapy of Breast Cancer: Scoring Systems and Beyond-Preliminary Results. EORTC, LI, PERCIST, RECIST, WHO
18  2015 MRI and ultrasound evaluation of invasive lobular carcinoma of the breast after primary systemic therapy. BCS, ILC, MRI, US
19  2015 Oncological safety of breast-conserving surgery after primary systemic chemotherapy in cT3-4 breast cancer patients. BCS, LR, LRFS
20  2015 Patterns of practice of regional nodal irradiation in breast cancer: results of the European Organization for Research and Treatment of Cancer (EORTC) NOdal Radiotherapy (NORA) survey. ALND, BC, BCS, ECE, EORTC, IMC, NORA, RNI, RT, SCN, SLN, TM
21  2015 Personalization of loco-regional care for primary breast cancer patients (part 1). ---
22  2015 Personalization of loco-regional care for primary breast cancer patients (part 2). ---
23  2015 Primary systemic therapy for breast cancer: Does the patient's involvement in decision-making create a new future? LABC
24  2015 Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study. CR, HER2, NPV, pCR, sens, SPEC
25  2015 Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients. HER2, pCR
26  2014 Photoacoustic mammography: initial clinical results. DCIS, IBC, MRI, PAM
27  2014 Prognostic relevance of induced and spontaneous apoptosis of disseminated tumor cells in primary breast cancer patients. BM, DTC
28  2013 A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study). HER2, pCR
29  2013 Detection of disseminated tumor cells in locally advanced breast cancer patients before primary systemic therapy. CR, DFS, DTC, LABC, OS
30  2013 The detection of pCR after PST by contrast-enhanced ultrasonography for breast cancer. CEUS, pCR
31  2013 The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer. Cx, TMA
32  2013 Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. BCSC, EMT, pCR, TILs
33  2012 Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer. ---
34  2012 Primary systemic therapy in HER2-amplified breast cancer: a clinical review. ---
35  2011 An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. CSC
36  2011 Breast cancer and primary systemic therapy. Results of the Consensus Meeting on the recommendations for pathological examination and histological report of breast cancer specimens in the Marche Region. ---
37  2011 Feasibility of sentinel lymph node biopsy in breast cancer patients with initial axillary lymph node metastasis after primary systemic therapy. ALN, ALND, AUS, CR, SLNB
38  2011 Intermediate endpoints of primary systemic therapy in breast cancer patients. ---
39  2011 International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). pCR
40  2011 Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy. CI, HER2, LTFU, OS, RFS
41  2011 [Responses to primary systemic therapy for breast cancer as assessed by hormone receptor and HER2 status]. DTX, EC, ER, HR, pCR, PgR, PTX
42  2010 Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099. 5-FU, DT, LABC, OS, pCR, RFS
43  2010 Primary systemic therapy with intermittent weekly paclitaxel plus gemcitabine in patients with stage II and III breast cancer: a phase II trial. pCR
44  2010 Sentinel lymph node biopsy is precise after primary systemic therapy in stage II-III breast cancer patients. ALND, SLNB
45  2008 Changes in tumour biological markers during primary systemic chemotherapy (PST). Bcl-2, ER, PR
46  2008 Epirubicin and cyclophosphamide followed by docetaxel as primary systemic chemotherapy in locally advanced breast cancer. CR, EC
47  2008 High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin. ER, ORR
48  2008 Locally advanced breast cancer: treatment guideline implementation with particular attention to low- and middle-income countries. BHGI, LABC
49  2008 Presurgical systemic treatment of nonmetastatic breast cancer: facts and open questions. cCR
50  2008 Primary systemic therapy in breast cancer: past lessons and new approaches. pCR
51  2008 Prognostic value of initial clinical disease stage after achieving pathological complete response. IBC, OS, pCR, RFS
52  2008 [A case of stage IV breast cancer in which a long-term no change state (NC) was attained by a combination of S-1 and TAM following AC-T as a primary systemic therapy (PST)]. ---
53  2008 [Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy]. HER2, pCR
54  2007 Clinical response by palpation during primary systemic therapy with four dose-dense cycles doxorubicin and docetaxel in patients with operable breast cancer: further results from a randomised controlled trial. pCR
55  2007 Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience. CI, pCR
56  2006 A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach. LABC, mRNA
57  2006 Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. DOC, pCR
58  2006 Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer. pCR
59  2006 Primary systemic therapy in operable breast cancer: clinical data and biological fall-out. ---
60  2006 Primary systemic therapy of breast cancer. pCR
61  2006 Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? IHC, NK
62  2006 [Clinical usefulness of MD-CT]. BCS, EIC
63  2006 [Primary systemic therapy in breast cancer: clinical and molecular factors predictors of outcome and response]. LABC
64  2005 Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. PgR
65  2005 Increased feasibility of weekly epirubicin and paclitaxel as neoadjuvant chemotherapy for locally advanced breast carcinoma. LABC, pCR
66  2005 Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer. pCR
67  2005 Weekly docetaxel/carboplatin as primary systemic therapy for HER2-negative locally advanced breast cancer. IBC
68  2005 Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. FAC, pCR
69  2004 Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study. DLTs, MTD, pCR
70  2004 Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy--a pilot study at 4 T. MR
71  2004 [Neoadjuvant therapy of breast cancer]. ---
72  2003 International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. ---
73  2003 Primary systemic therapy (PST) of locally advanced breast cancer using Doxorubicin/Docetaxel combination. ---
74  2002 Preoperative therapy in breast cancer: lessons from the treatment of locally advanced disease. LABC
75  2000 Early operable breast cancer. BCT
76  2000 Primary systemic therapy in operable breast cancer. BCT, DFS, OS, RCTs